Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,519,552
  • Shares Outstanding, K 77,692
  • Annual Sales, $ 10,680 K
  • Annual Income, $ -98,150 K
  • 60-Month Beta 1.76
  • Price/Sales 235.91
  • Price/Cash Flow N/A
  • Price/Book 11.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.20
  • Number of Estimates 9
  • High Estimate 0.22
  • Low Estimate -0.44
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +44.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.60 +23.75%
on 05/13/20
37.24 -14.93%
on 05/26/20
+5.09 (+19.14%)
since 05/01/20
3-Month
16.75 +89.13%
on 03/13/20
37.24 -14.93%
on 05/26/20
+2.48 (+8.49%)
since 02/28/20
52-Week
12.59 +151.63%
on 11/06/19
37.24 -14.93%
on 05/26/20
+12.40 (+64.32%)
since 05/31/19

Most Recent Stories

More News
Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy

Phase 1 Clinical Study to Evaluate Multiple Doses of FT538 as Monotherapy for Acute Myeloid Leukemia and in Combination with Anti-CD38 Monoclonal Antibody Therapy for Multiple Myeloma

FATE : 31.68 (-2.31%)
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of -15.79% and 21.62%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

FATE : 31.68 (-2.31%)
Fate Therapeutics: 1Q Earnings Snapshot

SAN DIEGO (AP) _ Fate Therapeutics Inc. (FATE) on Monday reported a loss of $33.5 million in its first quarter.

FATE : 31.68 (-2.31%)
Fate Therapeutics Reports First Quarter 2020 Financial Results and Highlights Operational Progress

Worldwide Collaboration Formed with Janssen for Novel iPSC-derived CAR NK and CAR T-Cell Product Candidates

FATE : 31.68 (-2.31%)
Should You Buy Fate Therapeutics (FATE) Ahead of Earnings?

Fate Therapeutics (FATE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

FATE : 31.68 (-2.31%)
What's in the Cards for Maxar (MAXR) This Earnings Season?

Lower revenues in the Space Infrastructure segment are likely to get reflected on Maxar's (MAXR) first-quarter 2020 results.

LOGI : 59.31 (-0.22%)
FATE : 31.68 (-2.31%)
GO : 36.03 (-2.12%)
MAXR : 16.41 (+8.89%)
Fate Therapeutics Announces Changes to its Board of Directors

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the...

FATE : 31.68 (-2.31%)
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2020 Financial Results

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that...

FATE : 31.68 (-2.31%)
Why Earnings Season Could Be Great for Fate Therapeutics (FATE)

Fate Therapeutics (FATE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

FATE : 31.68 (-2.31%)
Fate Therapeutics Announces Preclinical Data Presentation of Novel CAR MICA/B Cell-based Cancer Immunotherapy Program at the 2020 ASGCT Annual Meeting

Program Incorporates New CAR Constructs Designed to Specifically Target the Pan-tumor Associated Stress Proteins MICA and MICB

FATE : 31.68 (-2.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade FATE with:

Business Summary

Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California.

See More

Key Turning Points

2nd Resistance Point 32.96
1st Resistance Point 32.32
Last Price 31.68
1st Support Level 31.15
2nd Support Level 30.62

See More

52-Week High 37.24
Last Price 31.68
Fibonacci 61.8% 27.82
Fibonacci 50% 24.92
Fibonacci 38.2% 22.01
52-Week Low 12.59

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar